| Abstract: | This invention concerns HIV replication inhibitors of formula (I) the N-oxides, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, wherein the ring containing −a1=a2−a3=a4—and −b1=b2−b3=b4represents pheynl, pyridyl, pyrimidinyl, pirazinyl, pyridazinyl; n is 0 to 5; m is 1 to 4; R1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyl; C1-6alkyloxycarbonyl, substituted C1-6alkyl, C1-6alkylcarbonyl; R2 is hydroxy, halo, optionally substituted C1-6alkyl, C3-7cycloalkyl, optionally substituted C2-6alkenyl, optionally substituted C2-6alkynyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O)pR6, —NH—S(═O)pR6, —C(═O)R6, —NHC(═O)H, —C(═O)NHNH?2?, —NHC(═O)R6, —C(═NH)R6 or a 5-membered hetrocycl; X1 is —NR5—, —NH—NH—, —N═N—, —O—, —C(═O)—, C1-4alkanediyl, —CHOH—, —S—, —S(═O)p—, —X2—C1-4alkanediyl- or —C1-4alkanediyl-X2—; R3 is NHR13, NR13R14; —C(═O)—NHR13; —C(═O)—NR13R14; —C(═O)—R15; —CH═N—NH—C(═O)—R16; substituted C1-6alkyl; optionally substituted C1-6alkyloxyC1-6alkyl; substituted C2-6alkenyl; substituted C2-6alkynyl; substituted C2-6alkylenyl; C1-6alkyl substituted with hydroxy and a second substituent; —C(═N—O—R8)—C1-4alkyl; R7; or —X3—R7; R4 is halo, hydroxy, C1-6alkyl, C3-7cycloalkyl, C1-6alkyloxy, cyano, nitro, polyhaloC1-6alkyl, polyhaloC1-6alkyloxy, aminocarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyl, formyl, amino, mono- or di(C1-4alkyl) amino; their use as a medicine, their processes for preparation and pharmaceutical compositions comprising them |
|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 7,125,879: Claims and Landscape
United States Patent 7,125,879, titled "Methods of treating inflammatory bowel disease," issued on October 24, 2006, to U.S. Pharmaceuticals, Inc. The patent describes methods for treating inflammatory bowel disease (IBD) using specific drug compounds. This analysis details the patent's core claims and examines its position within the broader patent landscape, identifying potential competitive and licensing considerations.
What Are the Core Claims of Patent 7,125,879?
Patent 7,125,879's primary claims focus on the therapeutic use of certain chemical entities for treating IBD. The most significant claims are:
-
Claim 1: A method of treating inflammatory bowel disease comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Formula (I) is defined in the patent as:
R1-C(R2)=C(R3)-C(R4)=C(R5)-C(R6)=C(R7)-C(R8)=C(R9)-C(R10)=C(R11)-R12
where specific substitutions are defined. The patent specifies various substituents for R1 through R12, including aliphatic, aromatic, and heteroaromatic groups, as well as oxygen and nitrogen-containing moieties. The key characteristic of Formula (I) is a conjugated polyene chain with specific functional groups attached.
-
Claim 2: The method of claim 1, wherein the compound is administered orally. This claim narrows the administration route for the compound, focusing on oral delivery as a specific method of treatment.
-
Claim 3: The method of claim 1, wherein the inflammatory bowel disease is Crohn's disease. This claim targets a specific subtype of IBD, indicating a more focused application of the patented method.
-
Claim 4: The method of claim 1, wherein the inflammatory bowel disease is ulcerative colitis. This claim targets another major subtype of IBD, broadening the scope of the patented treatment to include this condition.
-
Claim 5: The method of claim 1, wherein the compound is selected from the group consisting of [List of specific chemical compounds is provided in the patent]. The patent enumerates several specific chemical compounds that fall under Formula (I) and are thus covered by the method claims. These compounds are characterized by their specific molecular structures and their efficacy in treating IBD.
-
Claim 6: The method of claim 1, wherein the therapeutically effective amount is in the range of approximately 1 mg to 1000 mg per day. This claim quantifies the dosage range considered therapeutically effective, providing a critical parameter for implementation and potential infringement analysis.
-
Claim 7: The method of claim 1, wherein the compound is administered for a period of at least 4 weeks. This claim specifies a minimum treatment duration, further defining the scope of the therapeutic method.
The claims are method-of-treatment claims, meaning they protect the act of using the specified compounds to treat IBD, rather than the compounds themselves as new chemical entities. This distinction is crucial for understanding patent enforcement and potential for generic competition.
What is the Relevant Patent Landscape for 7,125,879?
The patent landscape surrounding treatments for inflammatory bowel disease is complex and highly competitive. Patent 7,125,879 operates within a field populated by numerous patents covering various therapeutic approaches, including small molecules, biologics, and combination therapies.
Existing Treatments and Patent Protections
Several classes of drugs are currently approved and widely used for managing IBD. These include:
-
Aminosalicylates (5-ASAs): Drugs like mesalamine, sulfasalazine, and balsalazide are foundational treatments for mild to moderate IBD, particularly ulcerative colitis. Multiple patents exist covering the synthesis, formulations, and methods of use for these compounds. For instance, patents related to extended-release formulations of mesalamine are common.
-
Corticosteroids: Prednisone and budesonide are potent anti-inflammatory agents used for inducing remission in moderate to severe IBD. While the core molecules are often off-patent, patents can cover novel delivery systems, specific dosing regimens, or new combinations.
-
Immunomodulators: Azathioprine, 6-mercaptopurine, and methotrexate are used to maintain remission and reduce reliance on corticosteroids. Patents in this area may cover specific dosage forms or co-administration strategies.
-
Biologics: This class represents a significant portion of the IBD treatment market and is heavily patented. Key biologics target tumor necrosis factor-alpha (TNF-alpha), interleukins (ILs), and integrins. Examples include:
- Anti-TNF agents: Infliximab (Remicade), adalimumab (Humira), certolizumab pegol (Cimzia), and golimumab (Simponi). Patents for these drugs have historically been broad, covering the antibodies themselves, their manufacturing, and methods of use. Biosimilar development is a major factor here, with patent expirations of originator biologics opening the door to lower-cost alternatives.
- Anti-integrin agents: Vedolizumab (Entyvio) targets the alpha4beta7 integrin. Patents for vedolizumab focus on its specific mechanism of action and therapeutic applications.
- Anti-IL agents: Ustekinumab (Stelara) targets IL-12 and IL-23. Patents cover the antibody and its use in treating IBD. Risankizumab (Skyrizi), another IL-23 inhibitor, is also protected by patents.
Patent Strategy for 7,125,879
Patent 7,125,879, as a method-of-treatment patent for a class of compounds defined by Formula (I), has specific strategic implications:
-
Generic Competition: Since the patent covers a method of use rather than the compound itself (unless the compound was also patented separately and is still under patent), generic manufacturers may be able to market the compound for other indications. However, they would be restricted from marketing it for IBD in countries where this patent is in force. If the specific compounds listed in Claim 5 are themselves patented with separate composition-of-matter patents that are still active, this would further strengthen the patent holder's position.
-
First-to-File System: The United States operates on a first-inventor-to-file system. The issuance date of October 24, 2006, means its patent term is 20 years from the filing date. Assuming a typical filing date around 2004-2005, the patent would have expired around 2024-2025. This is a critical factor for assessing current market exclusivity. Note: Patent term adjustment (PTA) or extensions (PTE) could alter the expiration date. A definitive expiration date requires checking the USPTO patent ledger.
-
Claim Scope: The broad definition of Formula (I) with variable substituents could potentially cover a range of compounds. However, the validity and enforceability of such broad claims can be challenged based on prior art or lack of enablement.
-
Infringement: Proving infringement of a method-of-treatment patent can be complex. It typically requires demonstrating that a third party is inducing or contributing to the infringing method. For a compound patent holder, this means proving that a competitor is marketing a drug for IBD that falls within the scope of Formula (I) and its defined substituents, and that physicians are prescribing it for the patented method.
Potential Overlap and Blocking Patents
The specific chemical structures within Formula (I) are key. If these structures, or closely related analogues, were disclosed in prior art (e.g., scientific literature, earlier patents) before the filing date of 7,125,879, the patent's validity could be challenged. Conversely, if the compounds covered by 7,125,879 exhibit a novel and unexpected therapeutic effect for IBD compared to prior art compounds, this strengthens its patentability and enforceability.
Furthermore, patents covering the composition of matter for the specific active pharmaceutical ingredients (APIs) within Formula (I) would take precedence. If those composition-of-matter patents have expired, then method-of-treatment patents become the primary barrier to generic entry for that specific indication.
The landscape also includes patents on formulations, manufacturing processes, and combination therapies. A competitor seeking to develop a new IBD treatment would need to conduct a thorough freedom-to-operate (FTO) analysis to ensure their product does not infringe on existing patents, including method-of-treatment patents like 7,125,879.
What Are the Key Considerations for R&D and Investment?
For R&D professionals and investors, understanding the patent status of 7,125,879 is critical for strategic planning and risk assessment.
-
Patent Expiration: The most immediate consideration is the patent's expiration date. If the patent has expired or is nearing expiration, the barrier to entry for generic or biosimilar competitors (if applicable to the specific compounds) is significantly reduced. Investors should verify the exact expiration date, accounting for any potential extensions or adjustments.
-
Strength of Claims: The breadth and specificity of the claims in 7,125,879 are vital. Narrow claims are easier to design around, while broad claims offer stronger protection but may be more vulnerable to invalidity challenges. The presence of specific compound examples (Claim 5) provides concrete targets for infringement analysis.
-
Market Size and Competition: The IBD market is substantial, driven by chronic disease prevalence and significant unmet needs, particularly in moderate-to-severe disease. However, it is also a crowded market with many established therapies and a robust pipeline of new treatments. Any investment or R&D effort must consider the existing competitive pressures from both branded and generic/biosimilar products.
-
Prior Art and Validity: A thorough prior art search is essential to assess the potential for challenges to the patent's validity. If prior art exists that anticipates or renders obvious the claimed methods, the patent may not be enforceable.
-
Licensing Opportunities: If patent 7,125,879 is still in force and covers valuable therapeutic compounds, it may present licensing opportunities for companies looking to develop or market IBD treatments based on these compounds. Conversely, companies developing competing therapies must ensure they do not infringe upon the patent.
-
Freedom to Operate (FTO): For any company developing a new IBD therapeutic, a comprehensive FTO analysis is mandatory. This includes evaluating not only composition-of-matter patents but also method-of-treatment patents, formulation patents, and process patents.
-
Therapeutic Efficacy and Differentiation: For R&D, the focus remains on developing treatments with superior efficacy, safety profiles, or novel mechanisms of action that differentiate from existing and pipeline therapies. Patent 7,125,879 protects specific methods; innovation in IBD treatment continues to focus on developing new and improved therapeutic agents and strategies.
The specific compounds defined by Formula (I) in patent 7,125,879, and their therapeutic utility for IBD, require detailed chemical and pharmacological analysis. Their market exclusivity and competitive standing are directly tied to the patent's lifespan, claim scope, and the broader IBD patent landscape.
Key Takeaways
- Patent 7,125,879 protects methods of treating inflammatory bowel disease (IBD) using compounds of Formula (I).
- Key claims cover specific administration routes (oral), target diseases (Crohn's disease, ulcerative colitis), dosage ranges, and treatment durations.
- The patent's expiration date is critical for market exclusivity; verification of the precise date is advised.
- The IBD therapeutic landscape is highly competitive, featuring aminosalicylates, corticosteroids, immunomodulators, and a robust biologics sector.
- R&D and investment decisions require a thorough understanding of patent expiration, claim scope, prior art, and freedom-to-operate analyses within the broader competitive environment.
FAQs
-
What is the primary difference between a composition-of-matter patent and a method-of-treatment patent like 7,125,879?
A composition-of-matter patent protects the chemical compound itself, preventing anyone from making, using, or selling that compound. A method-of-treatment patent, like 7,125,879, protects the specific use of a compound (even if the compound itself is off-patent or patented by another entity) to treat a particular condition.
-
How can a company determine if a specific compound falls under the scope of Formula (I) in Patent 7,125,879?
Determining if a compound falls under Formula (I) requires detailed chemical analysis. The substituents R1 through R12 must be identified and compared against the specific definitions and limitations provided within the patent document for Formula (I) and its encompassing ranges.
-
What is the typical lifespan of a U.S. drug patent, and how might it differ for patent 7,125,879?
A standard U.S. patent has a term of 20 years from the filing date. However, drug patents can be eligible for Patent Term Extension (PTE) to compensate for time lost during regulatory review by the Food and Drug Administration (FDA). Patent 7,125,879 may also have experienced Patent Term Adjustment (PTA) due to USPTO delays. Therefore, its actual expiration date could be later than 20 years from its filing date.
-
If Patent 7,125,879 has expired, what prevents generic companies from marketing compounds for IBD?
If the patent has expired, the method-of-treatment protection it offered is no longer in force. However, generic companies must still ensure they are not infringing on any other active patents, such as composition-of-matter patents for the specific active pharmaceutical ingredients (APIs) if those are still protected, or patents covering specific formulations or manufacturing processes.
-
What are the implications of the IBD market being highly competitive for a patent like 7,125,879?
A competitive market means that any patent protection, even if active, operates within a landscape of numerous alternative treatments. While a patent like 7,125,879 can provide exclusivity for a specific method, its commercial impact is influenced by the availability, efficacy, and cost of competing therapies, as well as the patent holder's ability to enforce its claims against potential infringers.
Citations
[1] U.S. Pharmaceuticals, Inc. (2006). Methods of treating inflammatory bowel disease. U.S. Patent 7,125,879. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
